Mural Oncology(MURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MURA Mural Oncology

Trading 11-05 09:54:29 EST

3.37

-0.03

-1.03%

High3.37	Low3.30	Vol6.87K
Open3.30	D1 Closing3.40	Amplitude1.91%
Mkt Cap57.33M	Tradable Cap46.15M	Total Shares17.04M
T/O22.94K	T/O Rate0.05%	Tradable Shares13.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MURA","market":"US","secType":"STK","nameCN":"Mural Oncology","latestPrice":3.365,"timestamp":1730818207915,"preClose":3.4,"halted":0,"volume":6868,"delay":0,"floatShares":13715310,"shares":17037992,"eps":-10.330981,"marketStatus":"Trading","change":-0.035,"latestTime":"11-05 09:54:29 EST","open":3.3,"high":3.365,"low":3.3,"amount":22937.8556012,"amplitude":0.019118,"askPrice":3.38,"askSize":100,"bidPrice":3.34,"bidSize":405,"shortable":3,"etf":0,"ttmEps":-10.330981,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1730840400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.4,"postHourTrading":{"tag":"盘后","latestPrice":3.4,"preClose":3.4,"latestTime":"16:15 EST","volume":20,"amount":69.4,"timestamp":1730754923631},"volumeRatio":2.480249,"impliedVol":1.1675,"impliedVolPercentile":0.4215},"requestUrl":"/m/hq/s/MURA","defaultTab":"news","newsList":[{"id":"2481597552","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481597552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481597552?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:15","pubTimestamp":1730754900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA2XV4KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B64PRP62.GBP","BK4588","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","MURA","BK4585","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2481520465","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481520465","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481520465?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:15","pubTimestamp":1730754900,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass and DUBLIN, Nov.  04, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2974464/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","MURA","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2210149790.SGD","BK4585",".IXIC","NDAQ","BK4139","IE00B64PRP62.GBP","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2476140485","title":"HC Wainwright Initiates Coverage on Mural Oncology With Buy Rating, $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2476140485","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476140485?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:09","pubTimestamp":1729166951,"startTime":"0","endTime":"0","summary":"Price: 3.8300, Change: +0.11, Percent Change: +2.96","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MURA"],"gpt_icon":0},{"id":"2476146579","title":"Mural Oncology Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2476146579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476146579?lang=en_us&edition=fundamental","pubTime":"2024-10-17 19:09","pubTimestamp":1729163340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 17, 2024 07:09 ET (11:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2476711269","title":"Mural Oncology initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2476711269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476711269?lang=en_us&edition=fundamental","pubTime":"2024-10-17 18:11","pubTimestamp":1729159890,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Mural Oncology with a Buy rating and $18 price target Mural’s nemvaleukin alfa, an engineered interleukin-2 c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mural-oncology-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mural-oncology-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2476114901","title":"Mural Oncology Plc : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2476114901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476114901?lang=en_us&edition=fundamental","pubTime":"2024-10-17 18:04","pubTimestamp":1729159451,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nAZN2G2AO7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2473927084","title":"Mural Oncology initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2473927084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473927084?lang=en_us&edition=fundamental","pubTime":"2024-10-05 17:07","pubTimestamp":1728119243,"startTime":"0","endTime":"0","summary":"Raymond James analyst Laura Prendergast initiated coverage of Mural Oncology with a Strong Buy rating and $18 price target Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mural-oncology-initiated-with-a-strong-buy-at-raymond-james?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mural-oncology-initiated-with-a-strong-buy-at-raymond-james?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","LU1804176565.USD","LU0971096721.USD","IE00B64PRP62.GBP","LU1363072403.SGD","IE00BGHQF748.EUR","BK4588","BK4139","MURA","IE00B3QW5Z07.USD","LU2265009873.SGD","BK4585","RJF"],"gpt_icon":0},{"id":"2472937423","title":"Raymond James Initiates Mural Oncology at Strong Buy With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2472937423","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472937423?lang=en_us&edition=fundamental","pubTime":"2024-10-04 19:01","pubTimestamp":1728039696,"startTime":"0","endTime":"0","summary":"Raymond James Initiates Mural Oncology at Strong Buy With $18 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MURA","RJF"],"gpt_icon":0},{"id":"2472509789","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2472509789","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472509789?lang=en_us&edition=fundamental","pubTime":"2024-10-03 04:15","pubTimestamp":1727900100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and DUBLIN, Oct.  02, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/02/2957359/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","BK4588","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","MURA","BK4585","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2470781586","title":"Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2470781586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470781586?lang=en_us&edition=fundamental","pubTime":"2024-09-26 19:00","pubTimestamp":1727348400,"startTime":"0","endTime":"0","summary":"Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal mel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/26/2953676/0/en/Mural-Oncology-s-First-Virtual-Investor-Day-to-Highlight-Late-Stage-Clinical-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065732104.USD","BK4007","PROC","PRGS","BK4097","MURA","SSI","OS"],"gpt_icon":0},{"id":"2469978061","title":"Mural Oncology Appoints New Director and Audit Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2469978061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469978061?lang=en_us&edition=fundamental","pubTime":"2024-09-23 19:28","pubTimestamp":1727090901,"startTime":"0","endTime":"0","summary":"Mural Oncology Plc ( ($MURA) ) has shared an announcement. Mural Oncology plc has appointed Sachiyo Minegishi as a new independent director and Cha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mural-oncology-appoints-new-director-and-audit-chair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mural-oncology-appoints-new-director-and-audit-chair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MURA"],"gpt_icon":0},{"id":"2469943711","title":"Mural Oncology Strengthens Board of Directors With the Appointment of Sachiyo Minegishi","url":"https://stock-news.laohu8.com/highlight/detail?id=2469943711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469943711?lang=en_us&edition=fundamental","pubTime":"2024-09-23 19:00","pubTimestamp":1727089201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240923:nTUACVTVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2469194631","title":"Press Release: Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi","url":"https://stock-news.laohu8.com/highlight/detail?id=2469194631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469194631?lang=en_us&edition=fundamental","pubTime":"2024-09-23 19:00","pubTimestamp":1727089200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass and DUBLIN, Sept. 23, 2024  -- Mural Oncology plc , a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee.Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential, and reach, of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleuk","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA","BK4139"],"gpt_icon":0},{"id":"2466435835","title":"Mural Oncology to Host First Virtual Investor Day on September 26, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2466435835","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466435835?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:00","pubTimestamp":1725966000,"startTime":"0","endTime":"0","summary":"Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potentia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/10/2943492/0/en/Mural-Oncology-to-Host-First-Virtual-Investor-Day-on-September-26-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA","BK4588","BK4585","HST","BK4218","BK4139","BK4181"],"gpt_icon":0},{"id":"2466161788","title":"Buy Rating Affirmed for Mural Oncology Plc on Promising Clinical Trials and Innovative Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2466161788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466161788?lang=en_us&edition=fundamental","pubTime":"2024-09-09 20:15","pubTimestamp":1725884120,"startTime":"0","endTime":"0","summary":"Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Mural Oncology Plc (MURA – Research Report) and keeping the price target at $1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-mural-oncology-plc-on-promising-clinical-trials-and-innovative-cancer-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-mural-oncology-plc-on-promising-clinical-trials-and-innovative-cancer-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MURA"],"gpt_icon":0},{"id":"2465539480","title":"Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2465539480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465539480?lang=en_us&edition=fundamental","pubTime":"2024-09-05 04:30","pubTimestamp":1725481800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and DUBLIN, Sept.  04, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/04/2940930/0/en/Mural-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112",".IXIC","BK4585","BK4588","NDAQ","BK4139","LU2210150020.SGD","LU2210149790.SGD","MURA","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2462357168","title":"Mural Oncology to Present at Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2462357168","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462357168?lang=en_us&edition=fundamental","pubTime":"2024-08-27 19:00","pubTimestamp":1724756400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and DUBLIN, Aug.  27, 2024  (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/27/2936085/0/en/Mural-Oncology-to-Present-at-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","BK4139","LU1548497426.USD","LU0314104364.USD","IE00BZ1G4Q59.USD","BK4588","LU0971096721.USD","LU0320765646.SGD","LU1720051017.SGD","LU0225283273.USD","BK4581","BK4127","LU1363072403.SGD","LU1162221912.USD","LU1989772840.SGD","MURA","LU1074936037.SGD","LU1720051108.HKD","BK4534","IE00BKVL7J92.USD","BK4504","LU0106831901.USD","LU2357305700.SGD","LU1668664300.SGD","LU1989772923.USD","BK4585","LU0267386448.USD"],"gpt_icon":0},{"id":"2459790450","title":"Mural Oncology plc GAAP EPS of -$1.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2459790450","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459790450?lang=en_us&edition=fundamental","pubTime":"2024-08-13 21:57","pubTimestamp":1723557431,"startTime":"0","endTime":"0","summary":"Mural Oncology plc press release  (NASDAQ:MURA): Q2  GAAP EPS of -$1.86.\nAs of June 30, 2024, cash, cash equivalents, and marketable securities were $204.7 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4139167-mural-oncology-plc-gaap-eps-of-1_86","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MURA"],"gpt_icon":0},{"id":"2459297973","title":"Mural Oncology Q2 2024 GAAP EPS $(1.86) Up From $(3.01) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2459297973","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459297973?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:21","pubTimestamp":1723548072,"startTime":"0","endTime":"0","summary":"Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(1.86) per share. This is a 38.21 percent increase over losses of $(3.01) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40334192/mural-oncology-q2-2024-gaap-eps-1-86-up-from-3-01-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mural Oncology Q2 2024 GAAP EPS $(1.86) Up From $(3.01) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MURA"],"gpt_icon":0},{"id":"2459979502","title":"Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2459979502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459979502?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:15","pubTimestamp":1723547700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUA580G6Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065732104.USD","BK4139","BK4097","MURA","PRGS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.muraloncology.com","stockEarnings":[{"period":"1week","weight":-0.0634},{"period":"1month","weight":0.0119},{"period":"3month","weight":0.0119},{"period":"6month","weight":-0.126},{"period":"1year","weight":-0.9406},{"period":"ytd","weight":-0.4257}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.","exchange":"NASDAQ","name":"Mural Oncology","nameEN":"Mural Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mural Oncology(MURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mural Oncology(MURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mural Oncology,MURA,Mural Oncology股票,Mural Oncology股票老虎,Mural Oncology股票老虎国际,Mural Oncology行情,Mural Oncology股票行情,Mural Oncology股价,Mural Oncology股市,Mural Oncology股票价格,Mural Oncology股票交易,Mural Oncology股票购买,Mural Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mural Oncology(MURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mural Oncology(MURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}